[{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Radgocitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Radgocitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Delta-Fly Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Radgocitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Delta-Fly Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Delta-Fly Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Radgocitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Delta-Fly Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Delta-Fly Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Delta-Fly Pharma \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Radgocitabine

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.

                          Brand Name : DFP-10917

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 28, 2024

                          Lead Product(s) : Radgocitabine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.

                          Brand Name : DFP-10917

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 10, 2024

                          Lead Product(s) : Radgocitabine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.

                          Brand Name : DFP-10917

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          April 08, 2024

                          Lead Product(s) : Radgocitabine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          CPhI India 2024
                          Not Confirmed
                          CPhI India 2024
                          Not Confirmed

                          Details : DFP-10917 (radgocitabine) is a DNA polymerase inhibitor small molecule drug candidate which is being evaluated in combination with venetoclax for the treatment of acute myeloid leukemia.

                          Brand Name : DFP-10917

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          March 11, 2024

                          Lead Product(s) : Radgocitabine,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank